BSTK yields 15384.62% · ABBV yields 3.06%● Live data
📍 BSTK pulled ahead of the other in Year 1
Combined, BSTK + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BSTK + ABBV for your $10,000?
Brite-Strike Tactical Illumination Products, Inc. designs and manufactures tactical lighting products and solutions for the military, law enforcement, hunting, camping, outdoor recreation, and marine safety markets in the United States. The company provides Tactical Blue Dot series products, perimeter infrared intrusion security alert products, adhesive light strips, remote pressure switches, rolling illuminated distraction and disorientation devices, baton integrated lights, duty light cameras, basic tactical lights, observation cameras, police cycle and traffic safety gloves, executive precision lighting instruments, and helmet light attachment systems, as well as accessories, such as holsters, color lenses, and batteries. It also offers outdoor adventure and recreation products, including rechargeable lighted dog collars and leashes, adhesive light strips, outdoor adventure signal safety packs, camp alert perimeter security and survival signaling systems, and sport gloves; and citizens safety products comprising personal protection systems, personal alarms, and anodized aluminum LED multi-tools, as well as tactical flashlight instructor courses. The company is based in Plymouth, Massachusetts.
Full BSTK Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.